Thomas Schirrmann
Overview
Explore the profile of Thomas Schirrmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abassi L, Bertoglio F, Macak Safranko Z, Schirrmann T, Greweling-Pils M, Seifert O, et al.
Viruses
. 2023 Nov;
15(11).
PMID: 38005829
As of now, the COVID-19 pandemic has spread to over 770 million confirmed cases and caused approximately 7 million deaths. While several vaccines and monoclonal antibodies (mAb) have been developed...
2.
Lutz S, Klausz K, Albici A, Ebinger L, Sellmer L, Teipel H, et al.
Front Immunol
. 2023 Nov;
14:1227572.
PMID: 37965326
The activating receptor natural killer group 2, member D (NKG2D) represents an attractive target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by regulating the activity of...
3.
Diesterbeck U, Ahsendorf H, Frenzel A, Sharifi A, Schirrmann T, Czerny C
Vaccines (Basel)
. 2021 Nov;
9(11).
PMID: 34835240
A panel of potent neutralizing antibodies are protective against orthopoxvirus (OPXV) infections. For the development of OPXV-specific recombinant human single-chain antibodies (scFvs), the IgG repertoire of four vaccinated donors was...
4.
Roth K, Wenzel E, Ruschig M, Steinke S, Langreder N, Heine P, et al.
Front Cell Infect Microbiol
. 2021 Jul;
11:697876.
PMID: 34307196
Antibodies are essential molecules for diagnosis and treatment of diseases caused by pathogens and their toxins. Antibodies were integrated in our medical repertoire against infectious diseases more than hundred years...
5.
Bertoglio F, Fuhner V, Ruschig M, Heine P, Abassi L, Klunemann T, et al.
Cell Rep
. 2021 Jul;
36(4):109433.
PMID: 34273271
The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19). To develop human neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from...
6.
Dubel S, Herrmann A, Schirrmann T, Frenzel A, Hust M
Biospektrum (Heidelb)
. 2021 Feb;
27(1):46-48.
PMID: 33612989
COR-101 is a fully human, Fc silenced IgG that was discovered by antibody phage display. It reduced the SARS-CoV-2 virus load in the lung by more than 99 percent in...
7.
Dubel S, Hust M, Frenzel A, Schirrmann T
Biospektrum (Heidelb)
. 2020 Aug;
26(4):444-446.
PMID: 32834543
No abstract available.
8.
Behring S, Hansch R, Helmsing S, Schirrmann T, Schubert M
Hum Antibodies
. 2020 Mar;
28(2):149-157.
PMID: 32116242
Intrabodies are antibodies that are not secreted but bind to their antigens inside the cell producing them. Intrabodies targeting antigens in the endoplasmatic reticulum were successfully used in vitro and...
9.
Wezler X, Dubel S, Schirrmann T
Hum Antibodies
. 2018 Apr;
26(4):177-192.
PMID: 29689715
ImmunoRNases combine tumor targeting by antibodies with the cytotoxic action of ribonucleases from the RNase A superfamily. This study investigated for the first time all catalytic active human RNase A...
10.
Frenzel A, Kugler J, Helmsing S, Meier D, Schirrmann T, Hust M, et al.
Transfus Med Hemother
. 2017 Oct;
44(5):312-318.
PMID: 29070976
With six approved products and more than 60 candidates in clinical testing, human monoclonal antibody discovery by phage display is well established as a robust and reliable source for the...